PathologyWatch Named to Inc. 500 Fastest-Growing Companies in America

The leader in digital dermatopathology is recognized in the Health Services category of the prestigious list.

SALT LAKE CITYAugust 15, 2023Today, Inc. named PathologyWatch in the top 7 percent of America’s fastest-growing private companies on the annual Inc. 5000 list. This marks the first appearance on the list for the deep-learning AI company, which focuses on diagnostic and prognostic research for skin cancer.

Founded in 2017, PathologyWatch reached number 386 on the list of 5,000 companies for showcasing a remarkable 1500 percent growth from 2019 to 2022. This achievement makes PathologyWatch the list’s top-ranked health services company based in Utah. 

“It’s an incredible honor to have PathologyWatch recognized alongside so many notable companies on the Inc. 500 list,” said Dan Lambert, CEO and cofounder of PathologyWatch. “This acknowledgment is a testament to the perseverance and principles of our entire organization, including AI engineers, dermatopathologists, lab technicians, sales and marketing team, clients and everyone in between. Together, we’ve been able to continue our commitment to combine state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.” 

The ongoing prevalence of skin cancer in the United States is a driver in the demand for PathologyWatch’s comprehensive digital dermatopathology solutions. There are over 5 million cases of skin cancer detected every year in America, killing more than two people every hour and making it the country’s most common type of cancer. 

Lambert, a melanoma survivor, noted, “This Inc 500 recognition reinforces our mission to preserve and extend life for patients while reducing the cost of healthcare.” 

“Running a business has only gotten harder since the end of the pandemic,” said Inc. editor-in-chief Scott Omelianuk. “To make the Inc. 5000 — with the fast growth that it requires — is truly an accomplishment. Inc. is thrilled to honor the companies that are building our future.”

About PathologyWatch

PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.

PathologyWatch COO Scott Mattivi Collects Pittsburg State Honor

PathologyWatch COO Scott Mattivi was honored this month with the Meritorious Achievement Award from Pittsburg State University. The award is the highest honor based on career achievement bestowed by the university’s alumni association.

Mattivi graduated from the university, located in Pittsburg, Kansas, with a bachelor of science degree in biology in 1985 before earning a degree in medical technology from the University of Kansas in 1987.

“No matter where your career path eventually takes you, I think most people retain a soft spot for their alma mater, and that’s certainly the case for me,” says Mattivi. “To be recognized by Pittsburg State is truly an honor. My lifelong interest in science and healthcare was fostered there, and my education and association with Pittsburg State have definitely served me well in my career.”

In May of 2022, Mattivi joined PathologyWatch, which specializes in working with dermatology practices to manage their pathology workflows using a digital model. Mattivi brings strategic leadership and operational oversight to PathologyWatch’s three laboratories, which are located in Salt Lake City, UT, Phoenix, AZ, and Port Charlotte, FL.

Before arriving at PathologyWatch, Mattivi was president of Eurofins-Viracor BioPharma Services, where he worked for more than 13 years. Previous to that, he served as a laboratory manager at Quest Diagnostics for 22 years. Mattivi has earned his Six Sigma Green Belt Certification to ensure the highest quality of processes and services and serves on five different boards in the healthcare industry.

Along the way, Mattivi started programs with clinical lab students at the University of Kansas and Wichita State University to perform molecular science rotations at Viracor. He has been an advocate in sharing the virtues of seeking a career in clinical laboratory sciences with students at multiple regional educational institutions.

In addition to his Pittsburg State award, Mattivi will be honored later this year by the alumni association at the University of Kansas, where he will be recognized on October 6–7 as a distinguished health professions alumnus.

New CPT Codes Could Lead to Reimbursements for Digital Pathologists

By April Larson, MD

Thirteen is shaping up to be a very fortunate number for digital pathologists in 2023. Thanks largely to the efforts of the College of American Pathologists (CAP), the American Medical Association CPT Editorial Board developed 13 new Category III digital pathology digitization procedure codes. The 13 new add-on CPT codes, which have been introduced to record the use of digital pathology, went into effect on January 1.

Prior to 2023, lab reports in the US used the same CPT (current procedural terminology) codes in reporting any diagnostic readwith no distinction made as to whether the diagnosis utilized digital pathology or a glass slide under a microscope. Thus, both procedures earned the same reimbursement rates.

The new CPT codes will help track the additional work and investment of digital pathology into practice and help establish a new standard of care by demonstrating its wider acceptance and usage by the medical community, which in turn is a big step in receiving reimbursement for those services. This will continue to push the medical industry toward the adoption of digital pathology, increasing the availability of remote pathology work for pathologists. 

Let’s look at the difference between Category I and the new Category III CPT codes and how they could lead to reimbursement rates for those practices utilizing digital pathology.

The Difference Between CPT Codes

The 13 new Category III codes are designed to be temporary in nature. They’re intended for emerging technology, services, and procedures and allow for the data collection directly associated with carrying them out. The goal is to show that these procedures are becoming more commonly adopted so that pathologists can then work with the AMA to shift these codes to Category I status.

I believe the use of these new CPT codes is a helpful measure that the government can use to determine whether new technology—in this case, digital pathology and the use of AI prognostics— is actually advancing the standard of care. 

How do Category III codes differ from Category I codes? According to CAP, the new Category III codes may not meet one or more of the following Category I requirements:

  • All devices and drugs necessary for the performance of the procedure or service have received FDA clearance or approval when such is required for the performance of the procedure or service.
  • The procedure or service is performed by many physicians or other qualified health care professionals across the United States.
  • The procedure or service is performed with a frequency consistent with the intended clinical use (e.g., a service for a common condition should have high volume, whereas a service commonly performed for a rare condition may have low volume).
  • The procedure or service is consistent with current medical practice.
  • The clinical efficacy of the procedure or service is documented in literature that meets the requirements set forth in the CPT code change application.

Category III codes should be reported only for primary diagnostic use; they should not be reported if the digitization performed is solely for archival or educational purposes, developing a database for training or validation of AI algorithms, or for conference presentations.

The 13 new codes are attached to different services and procedures, but the one thing they all have in common is involving the digitization of glass slides.

The use of these codes is exciting both for dermatologists and dermatopathologists. What we’ve seen at PathologyWatch is that dermatopathologists can benefit from remote digital workflows, and dermatologists have quicker access to both digital slides and reports.

Reclassification to Category I codes, which is the goal, requires meeting both general and specific criteria as determined by the AMA.

Potential Game-Changer for Pathologists

While temporary in nature, the 13 new codes have the potential to be revolutionary for digital pathologists for a variety of reasons. Of primary merit is that the codes are widely expected to achieve Category I status in the near future, opening the door to new financial reimbursements.

Clearly, there are significant upfront expenses associated with digital pathology. The initial technology investment, for example, can seem formidable, with scanners running anywhere from $250,000 to $1 million.

While it is important to note that there are presently no reimbursements directly tied to the new CPT III codes, the change is laying the groundwork by bringing a different dynamic into play.

The utilization of CPT codes helps establish the frequency of usage within the medical community. In order to determine reimbursement, this is often determined by committees of experts who help document the financial investment required to use a new technology.

Much like radiology, the wide adoption of digital pathology will help improve the quality of patient care by promoting sharing of information and images with consulting providers, which improves communication and coordination of care. It also promotes more frequent peer-to-peer and expert consultation with difficult cases and patient education and understanding of their disease. 

Reimbursement also provides a financial incentive for clinics and labs to invest further in digital pathology. CAP proposals are being considered for development in the next few years through the AMA CPT process. In the meantime, it is important for dermatologists and dermatopathologists to use the new Category III codes to properly track their digital pathology services.

View a chart with the new CPT codes and detailed explanations of what they entail at Then, contact us to learn more about how these new codes, and the adoption of digital pathology, could greatly improve your level of patient care and your practice in general.

— April Larson, MD, is chief medical officer and a cofounder at PathologyWatch.

CEO Dan Lambert Says the Future Is Right Now for Digital Pathology

There is no time like the present to be part of the digital pathology field.

According to a 2022 report published by Facts and Factors Research, the global digital pathology market is expected to grow at a 13.8 percent CAGR increase in the next five years. In a recent Forbes article, Dan Lambert, CEO of PathologyWatch, spotlights several different market factors that are synergistically signaling exciting growth opportunities ahead.

Increased Demand for Remote Work

When the COVID-19 pandemic hit in 2020, many companies saw increased demand for the ability to work remotely. With a national emergency declared in the United States, the Centers for Medicare and Medicaid Services (CMS) waived some requirements for remote pathology sites. The ensuing three years have shown the benefits of digital pathology, especially as the demand for remote work remains high.

Lambert also sees digital pathology as a way to connect people in underserved areas with the latest technological advances in healthcare, which otherwise would not be accessible to them. “I predict that remote digital pathology will eventually help leapfrog the latest technology forward by connecting individual offices with dermpath experts and algorithms throughout the world,” Lambert writes.

New CPT Codes

The College of American Pathologists (CAP) worked with the AMA CPT Editorial Board in 2022 to develop a series of 13 new Category III digital pathology digitization procedure codes, which went into effect on January 1, 2023. Before the change, US labs used the same codes to report a diagnostic read, whether they were made under a microscope or using digital pathology.

The new codes will be used to track the extent to which digital pathology is being utilized, with the hope that it will soon result in additional reimbursement amounts, allowing those using the new technology to recoup some of their costs. 

“I see this change providing a clear financial incentive for labs to invest in digital pathology,” Lambert says.

Clinical Correlation

Digital pathology provides a more efficient means of communication between dermatologists and dermatopathologists. Where the old model functioned with biopsy samples placed on glass slides sent off to a lab, digital pathology streamlines the process by scanning the samples into digitized slides. Dermpaths now read the case digitally and can consult in real time with the originating dermatologist. 

“Quicker and more efficient diagnosis and communication can position the patient as the real beneficiary of digital pathology advancement,” says Lambert. ”In time, I predict that digital pathology and remote reads by experts will be the industry standard.” 

Single-Solution Systems

Until recently, most parts of the digital pathology process were handled separately. In the past, one company might have specialized in building viewers, while one developed diagnostic algorithms, and another specialized in the EMR systems that tracked each patient’s case. But now, vendors like PathologyWatch, with its Dermpath Optimization Tool, have developed systems that cohesively connect each step in the process.

“The fact that a few different vendors have developed start-to-finish systems is a good thing for digital pathology,” Lambert says. “[It] means the industry will continue shifting to support digital solutions.”

To read the full Forbes article, click here.

2023 Annual American Academy of Dermatology (AAD) Weekend Recap

We had a wonderful time at AAD’s annual conference held last weekend in New Orleans. With 8,500 health care professionals and over 16,000 total registrants, The Big Easy was bustling with the latest in pathology resources and expertise.

Here are a few of the highlights from the PathologyWatch team:

This year’s booth enjoyed a vibrant stream of dermatologists who were interested in learning about dot., the dermpath virtual assistant that helps derms to manage case workloads, view digital images and case files, create detailed pathology reports, and collaborate with colleagues.

Dr. Cacey Peters was on hand to demonstrate how dot. makes reviewing and annotating digital slides a snap for Derms and DermPaths. He also met with more than a few starstruck fans of his popular #GettingUnderYourSkin social media videos.

Though it isn’t polite to brag, we put our best foot forward by producing the show’s most memorable swag: custom socks featuring verruca vulgaris histology. That’s right, we gave warts to hundreds of happy derms.

In addition, a hot pot of Starbucks coffee is just what the doctors ordered to stay alert and keep their eyes on the prize. 

Friday evening we hosted our infamous annual AAD happy hour at Rosie’s On The Roof, which is located on top of the historic Higgins Hotel. Hundreds of Derms braved stormy conditions to join us for a classic fais do-do with bottomless hors d’oeuvres and drinks. 

Falling on St. Patrick’s Day, the place was packed with festive pathologists looking to let off a little steam and socialize between conference sessions. 

The patio’s city views offered the perfect location to reunite with familiar faces and make new friends.

At the end of the night, we gave away special edition “Show Me Some Skin” T-shirts, with the words “Don’t Worry, I’m a Dermatologist” emblazoned on the back. Based on the frenzy they created, the shirts will definitely be returning for AAD in San Diego 2024.

We also handed out custom Mardi Gras beads to get everyone in the spirit of the city’s rich traditions.

Looking back at our experience in New Orleans, we couldn’t be happier to be a part of this inspiring community. It was a joy to meet, answer questions, and share our vision with so many talented Derms. 

2023 promises to be a herald year for PathologyWatch, our customers and partners as we continue making great strides in the development of technology and workflows that enhance patient outcomes.

PathologyWatch’s Dan Lambert Named One of Top 35 Digital Health Leaders

Slice of Healthcare honors PathologyWatch CEO for innovative and influential leadership in digital health space.


Dan Lambert, CEO and cofounder of PathologyWatch, a full-service digital dermatopathology solution, was named one of the Top 35 Digital Health Leaders by Slice of Life Healthcare in its first annual list celebrating the most innovative and influential leaders in the digital health industry.

Slice of Healthcare is a top healthcare media company that produces and manages over 15 podcast shows featuring pivotal healthcare leaders as guests. Fundamental factors considered in selecting the top 35 honorees include their impact on the industry, outsider conversations, funding, partnerships signed, customers signed, experience, role and whether or not they exhibit the ever-elusive “it” factor.

“I am thrilled to be selected for this honor, but even more importantly, I’m excited for the recognition it brings to our mission at PathologyWatch,” said Lambert, who cofounded PathologyWatch in 2017. “Our goal is to bring truly life-saving technology to billions of people who might otherwise never have access to this level of healthcare. We have become excellent at one field of pathology by staying very focused on the study of skin cancer. The current and future capabilities of our single-solution system are very exciting, and we’re appreciative to be recognized by Slice of Healthcare.”

After receiving a degree from BYU in computer engineering, Lambert earned his MBA from Harvard Business School. A former executive at IBM, he has led multiple successful ventures and company exits to private equity. In 2018, Lambert was named an Inc 500 CEO for his work on BoardVitals, a medical education company.

“At PathologyWatch, Dan’s leadership style enables us to stay very focused on what we need to be doing to fulfill our mission,” says Michael Torno, Chief Revenue Officer. “It’s easy in a startup to go down all sorts of avenues and try to address everything all at once, because you see so many possibilities. What Dan does as a leader is keep us very engaged in doing something very, very well. It’s just crazy what he’s doing, and what he’s already done and accomplished. This latest recognition is well earned.”

The Slice of Healthcare Top 35 Digital Health Leaders list was compiled after an extensive internal and external research process that spanned more than six months. The final list showcases some of the industry’s most accomplished leaders in the digital health realm. Honorees include Chief Executive Officers, Chief Medical Officers, serial entrepreneurs, first-time founders and seasoned leaders.

“We are super excited to announce our first annual Top 35 Digital Health Leaders list,” said Jared S. Taylor, founder of Slice of Healthcare. “These leaders are making strides in digital health and adjacent areas, which is no easy task. We are proud to recognize their contributions and to bring attention to their innovative work.”

For more information about Slice of Healthcare and the 2023 Top 35 Digital Health Leaders, please visit For more information about PathologyWatch, visit

About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.